Next 10 |
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Results Demonstrate Significant Transdermal Penetration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 9, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI ), an innovative topical / transdermal pharmaceutical research and development company, today anno...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...
Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative pharmaceutical r...
Yoshiharu Global Co. (YOSH) is expected to report for Q1 2024 Analog Devices Inc. (ADI) is expected to report $1.26 for Q2 2024 Simplicity Esports (WINR) is expected to report for Q3 2024 Klepierre (KLPEF) is expected to report for Q1 2024 Synopsys Inc. (SNPS) is expected to repor...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
News, Short Squeeze, Breakout and More Instantly...
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Results Demonstrate Significant Transdermal Penetration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 9, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical ...
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI ), an innovative topical / transdermal pharmaceutical research and development company, today anno...